Ohr Pharmaceutical Inc
Form 10-Q
August 15, 2011

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2011

OR

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number: 333-88480

OHR PHARMACEUTICAL, INC.
(Exact name of registrant as specified in its charter)

Delaware	90-0577933
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

489 5th Avenue, 28th Floor
New York, NY 10017
(Address of principal executive offices)

(212) 682-8452
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this Chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer", "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	o	Accelerated filer	o
Non-accelerated filer Do not check if smaller reporting company	o	Smaller reporting company	x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes o No x

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date: 39,702,580 shares of Common Stock outstanding as of August 15, 2011.

OHR PHARMACEUTICAL, INC.
TABLE OF CONTENTS

PART I FINANCIAL INFORMATION

Item 1. Financial Statements.

The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission ("SEC"), and should be read in conjunction with the audited financial statements and notes thereto contained in the Company's Annual Report on Form 10-K filed with the SEC on January 13, 2011. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the periods presented have been reflected herein. The results of operations for the periods presented are not necessarily indicative of the results to be expected for the full year.

TABLE OF CONTENTS PAGE

OHR PHARMACEUTICAL, INC.
(A Development Stage Company)
Balance Sheets

ASSETS

CURRENT ASSETS	June 30, 2011 (Unaudited)	September 30, 2010
Cash	$878,538	$422,414
Prepaid expenses	31,854	34,889
Grant receivable	—	65,122
Security deposits	—	85,025
Total Current Assets	910,392	607,450
EQUIPMENT, net	20,416	24,168
OTHER ASSETS		
Patent costs, net	721,681	780,407
TOTAL ASSETS	$1,652,489	$1,412,025
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)		
CURRENT LIABILITIES		
Accounts payable and accrued expenses	$325,055	$332,772
Accrued salaries	—	5,453
Short-term notes payable	—	17,486
Convertible debentures	—	51,115
Total Current Liabilities	325,055	406,826
LONG-TERM LIABILITIES		
Stock warrant derivative liability	4,861,699	1,387,656
Total Long-term Liabilities	4,861,699	1,387,656
TOTAL LIABILITIES	5,186,754	1,794,482
STOCKHOLDERS' EQUITY (DEFICIT)		
Preferred stock, Series B; 15,000,000 shares authorized, at $0.0001 par value, 5,583,336 and 5,583,336 shares issued and outstanding, respectively	558	558
Common stock; 180,000,000 shares authorized, at $0.0001 par value, 39,702,580 and 35,452,580 shares issued and outstanding, respectively	3,970	3,545
Additional paid-in capital	22,178,436	21,587,433
Accumulated deficit	(21,628,748)	(21,628,748)
Deficit accumulated during the development stage	(4,088,481)	(345,245)
Total Stockholders' Equity (Deficit)	(3,534,265)	(382,457)

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$1,652,489	$1,412,025

The accompanying notes are an integral part of these financial statements.

OHR PHARMACEUTICAL, INC.
(A Development Stage Company)
Statements of Operations
(Unaudited)

	For the Three Months Ended June 30,		For the Nine Months Ended June 30,		From Inception of the Development Stage on October 1, 2007 Through June 30,
	2011	2010	2011	2010	2011
REVENUES	$—	$—	$—	$—	$ —
COST OF SALES	—	—	—	—	—
GROSS PROFIT	—	—	—	—	—
OPERATING EXPENSES					
General and administrative	228,387	340,096	517,362	613,544	2,853,927
Research and development	73,144	14,497	350,407	73,399	628,958
Total Operating Expenses	301,531	354,593	867,769	686,943	3,482,885
OPERATING LOSS	(301,531)	(354,593)	(867,769)	(686,943)	(3,482,885)
OTHER INCOME AND EXPENSE					
Interest expense	(84)	(2,495)	(2,433)	(19,288)	(49,723)
Gain/(Loss) on derivative liability	(2,835,983)	140,969	(2,945,196)	140,969	(1,464,610)
Gain on sale of assets	—	—	70,500	—	70,500
Other income and expense	50	39,514	1,662	68,101	159,824
Total Other Income and Expense	(2,836,017)	177,988	(2,875,467)	189,782	(1,284,009)
INCOME (LOSS) FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	(3,137,548)	(176,605)	(3,743,236)	(497,161)	(4,766,894)
PROVISION FOR INCOME TAXES	—	—	—	—	—
LOSS BEFORE	(3,137,548)	(176,605)	(3,743,236)	(497,161)	(4,766,894)
DISCONTINUED OPERATIONS					
Income from discontinued operations (including gain on disposal of $606)	—	—	—	—	678,413
Income tax benefit	—	—	—	—	—
GAIN ON DISCONTINUED OPERATIONS	—	—	—	—	678,413
NET LOSS	$(3,137,548)	$(176,605)	$(3,743,236)	$(497,161)	$ (4,088,481)
BASIC LOSS PER SHARE					
Continuing operations	$(0.08)	$(0.00)	$(0.10)	$(0.02)	
Discontinued operations	0.00	0.00	0.00	0.00	
	$(0.08)	$(0.00)	$(0.10)	$(0.02)	
WEIGHTED AVERAGE NUMBER OF					

SHARES OUTSTANDING:				
BASIC AND DILUTED	39,702,580	35,379,778	38,317,672	31,742,119

The accompanying notes are an integral part of these financial statements.

OHR PHARMACEUTICAL, INC.
(A Development Stage Company)
Statements of Stockholders' Equity (Deficit)

	Series B Preferred Stock Shares	Amount	Common Stock Shares	Amount	Additional Paid-in Capital	Accumulated Deficit	Deficit Accumulated During the Development Stage	Total Stockholders' Equity (Deficit)
Balance, September 30, 2009	5,583,336	$ 558	25,247,006	$ 2,525	$ 23,077,972	$ (21,628,748)	$ (839,622)	$ 612,685
Fair value of warrants granted	—	—	—	—	133,682	—	—	133,682
Fair value of employee stock options	—	—	—	—	219,541	—	—	219,541
Exercise of warrants for cash at $0.18 per share	—	—	5,583,336	558	1,004,442	—	—	1,005,000
Replacement warrants	—	—	—	—	(2,868,242)	—	—	(2,868,242)
Exercise of cashless warrants	—	—	4,547,238	455	(455)	—	—	—
Conversion of convertible debenture at $0.40 per share	—	—	25,000	2	9,998	—	—	10,000
Common stock issued for services at $0.21 per share	—	—	50,000	5	10,495	—	—	10,500
Net income for the year ended September 30, 2010	—	—	—	—	—	—	494,377	494,377
Balance, September 30, 2010	5,583,336	558	35,452,580	3,545	21,587,433	(21,628,748)	(345,245)	(382,457)
Fair value of employee stock options (unaudited)	—	—	—	—	35,925	—	—	35,925
Common stock and warrants issued for cash (unaudited)	—	—	4,200,000	420	520,733	—	—	521,153

Common stock issued for services at $0.20 per share(unaudited)	—	—	50,000	5	9,995	—	—	10,000
Warrants issued for services (unaudited)	—	—	—	—	24,350	—	—	24,350
Net loss for the nine months ended June 30, 2011 (unaudited)	—	—	—	—	—	—	(3,743,236)	(3,743,236)
Balance, June 30, 2011 (unaudited)	5,583,336	$ 558	39,702,580	$ 3,970	$ 22,178,436	$ (21,628,748)	$ (4,088,481)	$ (3,534,265)

The accompanying notes are an integral part of these financial statements.

OHR PHARMACEUTICAL, INC.
(A Development Stage Company)
Statements of Cash Flows
(Unaudited)

	For the Nine Months Ended June 30,		From Inception of the Development Stage on October 1, 2007 Through June 30,
	2011	2010	2011
OPERATING ACTIVITIES			
Net loss	$ (3,743,236)	$ (497,161)	$ (4,088,481)
Adjustments to reconcile net loss to net cash used by operating activities:			
Discontinued operations	—	—	(678,413)
Common stock issued for services	10,000	—	20,500
Fair value of warrants issued for services	24,350	296,128	452,604
Fair value of employee stock options	35,925	—	667,326
Gain on extinguishment of debt	—	(49,559)	(19,410)
Gain on sale of asset	(70,500)	—	(70,500)
(Gain) loss on derivative liability	2,945,196	(140,969)	1,464,610
Depreciation	3,752	—	4,602
Amortization of patent costs	58,726	—	78,319
Changes in operating assets and liabilities			
Prepaid expenses and deposits	3,035	(27,211)	(31,434)
Security deposits and other receivables	150,147	—	85,025
Accounts payable and accrued expenses	(13,170)	52,601	63,033
Net Cash (Used in) Operating Activities	(595,775)	(366,171)	(2,052,219)
INVESTING ACTIVITIES			
Proceeds from sale of asset	70,500	—	70,500
Purchase of equipment	—	—	(25,018)
Purchase of patents and other intellectual property	—	—	(300,000)
Discontinued operations	—	—	418,000
Net Cash Provided by Investing Activities	70,500	—	163,482
FINANCING ACTIVITIES			
Proceeds from preferred stock and warrants	—	—	1,005,000
Proceeds from common stock, derivative liability and warrants	1,050,000	—	1,050,000
Proceeds from warrants exercised for cash	—	1,005,000	1,005,000
Proceeds from related party payables	—	—	125,453
Repayments of related party payables	—	—	(125,453)
Proceeds from short-term notes payable	—	24,500	64,408

Repayments of short-term notes payable	(17,486)	(7,976)	(64,408)
Repayment of convertible debentures	(51,115)	(401,156)	(490,000)
Net Cash Provided by Financing Activities	981,399	620,368	2,570,000
NET INCREASE IN CASH	456,124	254,197	681,263
CASH AT BEGINNING OF PERIOD	422,414	345,604	197,275
CASH AT END OF PERIOD	$ 878,538	$ 599,801	$ 878,538

The accompanying notes are an integral part of these financial statements.

OHR PHARMACEUTICAL, INC.
(A Development Stage Company)
Statements of Cash Flows
(Unaudited)

	For the Nine Months Ended June 30,		From Inception of the Development Stage on October 1, 2007 Through June 30,
	2011	2010	2011
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION			
CASH PAID FOR:			
Interest	$ 2,374	$ 30,963	$ 48,294
Income Taxes	—	—	—
NON CASH FINANCING ACTIVITIES:			
Transfer of investment for dividends payable	$ —	$ —	$ 186,000
Purchase of patents for debenture	—	—	500,000
Conversion of debenture	—	10,000	10,000
Options issued to settle accounts payable	—	—	3,991

The accompanying notes are an integral part of these financial statements.

OHR PHARMACEUTICAL, INC.
(A Development Stage Company)
Notes to the Financial Statements
June 30, 2011 and September 30, 2010

NOTE 1 – CONDENSED FINANCIAL STATEMENTS

The accompanying financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at June 30, 2011, and for all periods presented herein, have been made.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company's September 30, 2010 audited financial statements. The results of operations for the periods ended June 30, 2011 and 2010 are not necessarily indicative of the operating results for the full years.

NOTE 2 - GOING CONCERN

The Company's financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and allow it to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. If the Company is unable to obtain adequate capital, it could be forced to cease operations. The Company has had no revenues and has generated an accumulated deficit of approximately $25,717,229 ($4,088,481 accumulated during the development stage) as of June 30, 2011.

In order to continue as a going concern, the Company will need, among other things, additional capital resources. Management's plan is to obtain such resources for the Company by seeking equity and/or debt financing. However management cannot provide any assurances that the Company will be successful in accomplishing any of its plans.

The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually secure other sources of financing and attain profitable operations. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Reclassification of Financial Statement Accounts

Certain amounts in the June 30, 2010 financial statements have been reclassified to conform to the presentation in the June 30, 2011 financial statements.

Recent Accounting Pronouncements

Management has considered all recent accounting pronouncements issued since the last audit of the Company's financial statements. The Company's management believes that these recent pronouncements will not have a material effect on the Company's financial statements.

NOTE 4 – PATENT COSTS

Patent costs represent the capitalized purchase price of assets acquired in the secured party sale as part of the Company's previously announced strategy to create a rollup of undervalued biotechnology companies and assets. As of June 30, 2011, the Company had purchased $800,000 worth of biotechnology patents and other intellectual property. In these acquisitions, the Company used approximately $300,000 in cash and issued a $500,000 convertible debenture for the remainder of the cost which was secured by the acquired assets and was repaid.

The Company amortizes the patents over their remaining useful lives. During the nine months ended June 30, 2011 and 2010, the Company recognized $58,726 and $-0- in amortization expense on the patents, respectively. The amortization expense has been included in research and development expense.

NOTE 5 – OTHER ASSETS

During the nine months ended June 30, 2011, the Company sold certain non-core assets for $87,500. The assets sold were acquired as part of a purchase of a larger portfolio of patents. The assets were not part of the targeted biotechnology sector strategy and management did not expect to be able to use or sell these assets during their useful lives and thus assigned an initial value of $0 to these assets. As part of the transaction, the Company incurred a broker's fee of $17,000. Accordingly, the Company recognized a gain on the sale of assets of $70,500.

NOTE 6 – CONVERTIBLE DEBT

During the year ended September 30, 2009, the Company issued an 11% convertible note in the amount of $500,000, due June 20, 2011. Under the terms of the note, the Company paid $180,000 on December 15, 2009, and quarterly payments of $25,000 commencing on March 30, 2010, each of which was applied first towards the satisfaction of accrued interest and then towards the satisfaction of principal. All unpaid principal and accrued interest on the notes was convertible into shares of the Company's common stock at the election of the purchasers at any time at the conversion price of $0.40 per share. On June 23, 2010 the holder of the note converted $10,000 of principal into 25,000 shares of common stock at $0.40 per share. On December 29, 2010, the Company repaid the balance of the convertible note in full including all accrued interest. Accordingly, the security interest issued in connection with the note was released.

NOTE 7 – DERIVATIVE LIABILITY AND FAIR VALUE MEASUREMENTS

Effective July 31, 2009, the Company adopted ASC Topic No. 815-40 which defines determining whether an instrument (or embedded feature) is solely indexed to an entity's own stock. On January 15, 2010 the Company issued 5,583,336 warrants with an exercise price of $0.55 to warrant holders that had exercised warrants during the period at $0.18. On December 30, 2010 the Company issued 2,520,000 warrants with an exercise price of $0.55 that were attached to shares sold to a group of institutional and accredited investors for gross proceeds of $1,050,000.

The exercise price of both sets of these warrants are subject to "reset" provisions in the event the Company subsequently issues common stock, stock warrants, stock options or convertible debt with a stock price, exercise price or conversion price lower than $0.18 and $0.25, respectively. If these provisions are triggered, the exercise price of all their warrants will be reduced. As a result, the warrants are not considered to be solely indexed to the Company's own stock and are not afforded equity treatment.

The fair value of the derivative liability was calculated using a Lattice Model that values the compound embedded derivatives based on future projections of the various potential outcomes. The assumptions that were analyzed and incorporated into the model included the conversion feature with the full ratchet and weighted average anti-dilution

reset, expectations of future stock price performance and expectations of future issuances based on the Company's prior stock history, prior issuances of stock, and expected capital requirements. Probabilities were assigned to various scenarios in which the reset provisions would go into effect and weighted accordingly.

The total fair value of the warrants issued on January 15, 2010, amounting to $2,868,242 has been recognized as a derivative liability on the date of issuance with all future changes in the fair value of these warrants being recognized in earnings in the Company's statement of operations under the caption "Other income (expense) – Gain (loss) on warrant derivative liability" until such time as the warrants are exercised or expire. Because these warrants were issued in conjunction with common stock that had been exchanged for warrants with an exercise price of $0.18, the fair value on the date of issuance includes the net cash proceeds from the sale of stock of $1,005,000 and the fair value of $0.18 warrants being forfeited valued on the date of exercise at $2,867,856.

The total fair value of the warrants issued on December 30, 2010, amounting to $528,847 has been recognized as a derivative liability on the date of issuance with all future changes in the fair value of these warrants being recognized in earnings in the Company's statement of operations under the caption "Other income (expense) – Gain (loss) on warrant derivative liability" until such time as the warrants are exercised or expire. The total cash proceeds of $1,050,000 were first applied to the warrants with the remaining $521,153 allocated to the common shares and recorded in additional paid-in capital.

ASC 815 requires Company management to assess the fair market value of certain derivatives at each reporting period and recognize any change in the fair market value as another income or expense item. The Company's only two assets or liabilities measured at fair value on a recurring basis are its derivative liabilities associated with the above warrants. At June 30, 2011, the Company revalued the warrants and determined that, during the nine months ended June 30, 2011, the Company's derivative liability increased by $2,945,196 to $4,861,699. The Company recognized a corresponding loss on derivative liability in conjunction with this revaluation.

NOTE 8 – CAPITAL STOCK

On December 15, 2009, investors exercised 5,583,336 Series G warrants via a cashless exchange for 4,547,238 shares of the Company's common stock.

On January 15, 2010, the Company completed a $1,005,000 financing in which the Company issued 5,583,336 common shares to holders of the Series F Warrants who exercised their warrants at an exercise price of $0.18. Additionally, as an inducement to the holders to exercise the Warrants, the Company issued 5,583,336 Series H warrants to the Series F warrant holders who exercised their Series F warrants. The Series H Warrants have a 5 year term with a strike price of $0.55.

On June 23, 2010 the holder of the convertible debenture elected to convert $10,000 of the remaining principal balance into 25,000 common shares at $0.40 per share pursuant to the conversion rights of the note.

On August 5, 2010 the Company issued 50,000 shares of its common stock to a consultant for services to be provided to the Company. The shares were valued at $0.21 per share based on the market price of the shares on the date of issuance. The Company recorded the corresponding $10,500 expense to general and administrative expense.

On November 5, 2010 the Company issued 50,000 shares of common stock to a consultant for services. The shares were valued at $0.20 per share based on the market price of the shares on the date of issuance. The Company recorded the corresponding $10,000 expense to general and administrative expense.

On December 30, 2010 the Company sold 4,200,000 shares of common stock to a group of institutional and accredited investors for gross proceeds of $1,050,000. As of December 31, 2010 the Company had received $595,000 in cash and recorded a stock subscription receivable for the remaining $455,000, of which all had been received as of February 14, 2011. In addition, the investors received 2,520,000 five year warrants to purchase common stock at an exercise price of $0.55 per share valued at $528,847, leaving a net of $521,153 for the value of the shares issued.

NOTE 9 - WARRANTS

The Company has determined the estimated value of the warrants granted to employees and non-employees in exchange for services and financing expenses using the Black-Scholes pricing model and the following assumptions: stock price at valuation, $0.21-$0.52; expected term of 3-5 years, exercise price of $0.50-$0.60, a risk free interest rate of 1.15-2.60%, a dividend yield of 0% and volatility of 132-435%.

Between October 29 and December 4, 2009, the Company issued a total of 236,000 warrants for services rendered to the Company. As a result of this issuance, the Company recognized $88,562 in consulting expense.

On April 9, 2010 the Company granted 10,000 warrants as payment for an outstanding accounts payable balance of $3,991.

On June 22, 2010 the Company authorized the issuance of 93,000 warrants for services to the Company. Of these authorized warrants, 90,000 were issued on June 23, 2010 once the contract for services was finalized. These warrants have a 5 year term with a strike price of $0.50. The remaining 3,000 warrants were issued September 2, 2010. These warrants have a 3 year term with a strike price of $0.50. The combined value of these warrants was $41,129 at the time of issuance and the value was expensed as research and development expense.

In connection with the December 30, 2010, financing, the investors received 2,520,000 five year warrants to purchase common stock at an exercise price of $0.55 per share. The exercise price of these warrants contains certain reset

provisions which require the fair value of the warrants to be reported as a liability and not in permanent equity. On the date of issuance, the Company calculated the fair value of these warrants to be $528,847 (see note 7). The total cash proceeds of $1,050,000 were first applied to the warrants with the remaining $521,153 being allocated to the common shares and being recorded in additional paid-in capital.

Between May 12 and June 13, 2011, the Company issued a total of 355,000 warrants for services rendered to the Company. Of these warrants, 55,000 vest immediately and 300,000 vest over a 12 month period and will be recognized over the term of the agreement. As a result of this issuance, the Company recognized $24,350 in consulting expense.

NOTE 9 – WARRANTS (CONTINUED)

Below is a table summarizing the warrants issued and outstanding as of June 30, 2011.

Date Issued	Number Outstanding	Exercise Price	Contractual Life (Years)	Expiration Date	Value if Exercised
Balance 10/1/08	13,509,857	1.18	5	Various	15,941,631
03/20/09	5,000,000	0.50	5	03/31/14	2,500,000
06/03/09	11,166,672	0.18	5	06/03/14	2,010,001
09/30/09	150,000	0.40	5	06/30/14	60,000
Expired	—	—	—	—	—
Balance 9/30/09	29,826,529	0.69	—	—	20,511,632
10/09/09	88,000	0.50	5	10/29/14	44,000
11/09/09	18,000	0.50	5	11/09/14	9,000
12/04/09	130,000	0.60	2	12/04/11	78,000
12/15/09	(5,583,336)	0.18	—	—	(1,005,000)
01/15/10	5,583,336	0.55	5	01/15/15	3,070,835
01/15/10	(5,583,336)	0.18	—	—	(1,005,000)
04/13/10	10,000	0.55	5	04/13/15	5,500
07/23/10	93,000	0.50	3	07/23/13	46,500
Expired	—	—	—	—	—
Balance 9/30/10	24,582,193	0.89	—	—	21,755,467
12/30/10	2,520,000	0.55	5	12/30/15	1,386,000
05/12/11	25,000	0.50	5	5/12/2016	12,500
05/12/11	30,000	0.50	5	5/12/2016	15,000
06/13/11	25,000	0.50	2	6/13/2013	12,500
Expired	(1,090,568)	1.19	—	—	(1,297,776)
Balance 6/30/11	26,091,625	0.84	—	—	21,883,691

NOTE 10 – OPTIONS

On April 12, 2010 the Company granted 1,000,000 options to employees as part of its 2009 stock option plan. The Company used the Black-Scholes option pricing model to calculate the fair market value of these options. Using the assumptions in the table below, the Company calculated a fair value of $0.40 per option. Of the 1,000,000 options issued, 520,000 vested upon issuance and the remaining 480,000 will vest over the 5 year life of the options. In the nine month period ended June 30, 2011, the Company recognized compensation expense of $35,925 for the vested options.

Stock Price at Valuation Date	$0.40	
Exercise (Strike) Price	$0.50	
Dividend Yield	0.00	%
Years to Maturity	5.00	
Risk-free Rate	2.60	%
Volatility	277	%

Below is a table summarizing the options issued and outstanding as of June 30, 2011.

Date	Number	Exercise	Contractual	Expiration	Value if

Issued	Outstanding	Price	Life (Years)	Date	Exercised
Prior 10/1/2008	—	$ —	—	—	$ —
04/09/09	579,141	0.65	5	04/09/13	376,442
Balance 09/30/09	579,141	0.65	—	—	376,442
04/12/10	1,000,000	0.50	5	04/12/15	500,000
Balance 09/30/10	1,579,141	$ 0.56	—	—	$ 876,442
Issued	—	—	—	—	—
Expired	(32,176)	0.65	—	—	(20,914)
Balance 6/30/11	1,546,965	$ 0.55	—	—	$ 855,528

NOTE 11 – SUBSEQUENT EVENTS

On July 7, 2011, the Company entered into a consulting agreement for clinical trials and other services to be provided to the Company over a 12 month period. As compensation, the Company has agreed to issue warrants to purchase 100,000 shares of the Company's common stock. The warrants have an exercise price of $0.54 per share, and are exercisable for five years. In addition, the Company has agreed to issue 120,000 warrants to purchase common stock, vesting in equal tranches of 30,000 warrants per quarter. Such warrants will have an exercise price equal to the Company's market price at the time of each vesting tranche, and be exercisable for a period of five years.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

Certain statements contained in this report, including, without limitation, statements containing the words "believes," "anticipates," "expects," "intends," and words of similar import, constitute "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 or by the Securities and Exchange Commission in its rules, regulations and releases, regarding the Company's financial and business prospects. These forward-looking statements are qualified in their entirety by these cautionary statements, which are being made pursuant to the provisions of such Act and with the intention of obtaining the benefits of the "safe harbor" provisions of such Act. The Company cautions investors that any forward-looking statements it makes are not guarantees of future performance and that actual results may differ materially from those in the forward-looking statements. We assume no obligation to update any forward-looking statements contained in this report, whether as a result of new information, future events or otherwise. Any investment in our common stock involves a high degree of risk. For a general discussion of some of these risks in greater detail, see our "Risk Factors" in the Company's Annual Report on Form 10-K (the " Form 10-K ") for the fiscal year ended September 30, 2010, as filed with the Securities and Exchange Commission on January 13, 2011.

History and Recent Events

Ohr Pharmaceutical, Inc. ("we", "Ohr", the "Company" or the "Registrant") is a Delaware corporation that was organized on August 4, 2009. On that date, the predecessor firm (formerly known as BBM Holdings, Inc. and Prime Resource, Inc., organized on March 29, 2002) completed a reincorporation merger with its wholly-owned subsidiary, Ohr Pharmaceutical, Inc., and ceased to exist as a separate legal entity. The reincorporation merger did not result in any material change in our business, offices, facilities, assets, liabilities, obligations or net worth, or our directors, officers or employees.

On March 19, 2009, the Company acquired in a secured party sale all the patents, related intellectual property, clinical data and other assets related to AVR118 (also known now as OHR/AVR118). OHR/AVR118 is in an ongoing Phase II trial for the treatment of cachexia. The Company also exercised its option to acquire the new technology and early stage pharmaceutical compounds from Dr. S. Z. Hirschman, who joined the Company as a consultant and Chief Scientific Advisor.

The Company acquired OHR/AVR118 and related assets in a secured party sale with $100,000 in cash and $500,000 principal amount of 11% convertible secured non-recourse debenture due June 20, 2011 convertible into common stock at $0.40 per share (the "Convertible Debenture"). The Convertible Debenture was repaid in full on December 29, 2010. The cash portion of the purchase price was financed by short-term loans from an affiliate of Orin Hirschman and another current shareholder, which were repaid June 3, 2009.

On August 19, 2009, the Company completed the acquisition of Squalamine, Trodusquemine and related compounds from Genaera Liquidating Trust. The Company paid $200,000 in cash for the compounds.

On April 12, 2010, Dr. Irach Taraporewala was hired as the Company's full-time CEO and Sam Backenroth was hired as the Company's Vice President of Business Development and Interim CFO. In connection with their employment, Mr. Limpert resigned as an officer and director of the Company.

On December 14, 2010 the Company announced the opening of a new clinical site for its ongoing Phase II clinical trial to investigate the efficacy of OHR/AVR118 for the treatment of cancer cachexia at the Ottawa Hospital Cancer Centre.

On June 21, 2011, the Company announced the topical Squalamine program and its intention to move the program forward into clinical trials for the treatment of the wet form of age-related macular degeneration. The Company also

announced preclinical animal results using the topical Squalamine formulation on July 13, 2011.

Product Pipeline

Squalamine

Squalamine is an anti-angiogenic small molecule with a novel intracellular mechanism of action, that counteracts not only Vascular Endothelial Growth Factor (“VEGF”) but also other angiogenic growth factors such as Platelet Derived Growth Factor (”PDGF”). Recent clinical evidence has shown PDGF to be an additional target for the treatment of Wet Age-related Macular Degeneration (“Wet-AMD”). Using the intravenous formulation in over 250 patients in Phase 1 and Phase 2 trials for the treatment of Wet-AMD, Squalamine demonstrated good safety and efficacy in both early and advanced Wet-AMD. Ohr reformulated Squalamine for ophthalmic indications from an intravenous infusion (“IV”)

to a topical eye drop. The Company plans on advancing its clinical Wet-AMD program with the novel topical formulation. The topical formulation is designed for enhanced uptake to the back of the eye and decreased potential for side effects. The previous IV formulation had been awarded fast track status and a Special Protocol Assessment for a phase III registration study from the U.S. Food and Drug Administration ("FDA").

In Phase II intravenous clinical trials, stabilization or improvement in visual activity was observed in the vast majority of patients, with both early and advanced lesions responding and few drug-related ocular or systemic effects were observed. In a number of patients whose Wet-AMD had progressed to an advanced stage ("fellow eye"), the administration of Squalamine produced beneficial effects and significant improvement in best corrected visual acuity ("BCVA"). As opposed to the approved current standard of care therapy, Squalamine does not require direct injection into the eye.

The Company has conducted preclinical testing on the novel topical formulation with the following results:

Ocular tolerance and toxicity: In a dose escalation safety study involving daily eye drop treatment in Dutch belted rabbits over a 28 day period, the formulation proved safe, and exhibited no signs of ocular toxicity or changes in intraocular pressure. Importantly, no macroscopic or histopathological changes to the ocular tissues were noted.

Biodistribution study: A single eye drop was administered to the front of the eye in Dutch belted rabbits. At all evaluated timepoints, drug concentrations in the posterior sclera-choroid region behind the retina at the back of the eye exceeded the tissue concentrations of Squalamine that are known to block the choroidal neovascularization process in wet-AMD. The study results also demonstrated that the drug was undetectable in the anterior chamber of the eye (aqueous humor), confirming that it does not penetrate through all the layers of the cornea or contact the lens.

Additionally, Squalamine has shown promise in the treatment of solid tumors such as ovarian cancer. In a Phase IIa study, patients with stage III and IV refractory and resistant ovarian cancer received Squalamine in conjunction with another chemotherapeutic agent with approximately two thirds of the patients achieving a complete response, partial response or stable disease. In 2001, Squalamine was awarded Orphan Drug Status by the Food and Drug Administration ("FDA") for the treatment of late stage resistant and refractory ovarian cancer. Because of funding constraints, Ohr is seeking a development partner to further advance development of this indication.

OHR/AVR118

OHR/AVR118 is a novel immunomodulator with a singular chemical structure that is terminally sterilized and endotoxin-free. The compound is composed of two small peptides, Peptide A, which is 31 amino acids long, and Peptide B, that is 21 amino acids long. Peptide B is unique in that the dinucleotide, diadenosine, is covalently attached to serine at position 18 through a phosphodiester bond. OHR/AVR118 is quite stable and has a very favorable safety profile both in animal toxicity studies and in human clinical trials.

Ohr is currently conducting a Phase II clinical trial of OHR/AVR 118 for the treatment of cancer cachexia at a leading cancer center in Canada. Cancer cachexia is a severe wasting disorder characterized by weight loss, muscle atrophy, fatigue, weakness, and significant loss of appetite. This disorder is often seen in late stage cancer patients. OHR/AVR118 has also shown to have chemoprotective effects, thus potentially allowing patients to better tolerate chemotherapy and radiation as well as more intensive treatment regimens with ordinary toxic chemotherapeutic agents, while maintaining body weight and avoiding other side effects. There is currently no FDA approved drug for the treatment of cancer cachexia. The Company presented interim data on this current trial at the annual conference of the Society of Cachexia and Wasting Disorders in Barcelona, Spain in December 2009. On December 14, 2010, the Company announced the opening of a new clinical site for the ongoing Phase II trial in cancer cachexia at the Ottawa

Hospital Cancer Centre and the enrollment of the first three patients at the new site.

General

The Company is a biotechnology rollup company currently focused on development of the Company's previously acquired compounds. With the addition of our executive management team in April 2010, we have shifted our strategy accordingly to focus on the development of our two later stage lead products, OHR/AVR 118 for the treatment of cancer cachexia, and Squalamine for the treatment of Wet-AMD. We acquired OHR/AVR118 in a secured party sale and Squalamine from the Genaera Liquidating Trust as part of the Company's previous strategy to create a rollup of undervalued biotechnology companies and assets.

We seek to advance our two lead products through later stage clinical trials as well as developing some of our earlier stage products and indications that we are moving forward with minimal capital outlay. We have also started a new initiative to seek and implement strategic alternatives with respect to our products, including licenses, business collaborations and other business combinations or transactions with other

pharmaceutical and biotechnology companies. From time to time, we may engage in discussions with third parties regarding the licensure, sale or acquisition of our products and technologies or a merger or sale of the Company; however we currently do not have plans to enter into such a transaction and there is no assurance that the Company will complete such a transaction.

The Company has limited core operating expenses as we have only two full-time employees. In connection with the hiring of our executive management team, we have established an office in New York City. The office is being provided by an affiliate of Mr. Backenroth free of charge with the exception of minimal office related expenses.

The Company will continue to incur ongoing operating losses, which are expected to increase substantially as it funds development of the new pharmaceutical compounds. In addition, losses will be incurred in paying ongoing reporting expenses, including legal and accounting expenses, as necessary to maintain the Company as a public entity. No projected date for potential revenues can be made, and the Company is undercapitalized at present to completely develop, test and market any pharmaceutical product.

Until the Company is able to generate significant revenue from its principal operations, it will remain classified as a development stage company. The Company can give no assurance that it will be successful in such efforts or that its limited operating funds will be adequate to support the Company's operations, nor can there be any assurance of any additional funding being available to the Company. Our independent accountants have qualified their audit report by expressing doubt about the Company's ability to continue as a "going concern."

Liquidity and Sources of Capital

The Company has insufficient capital to pay for development of its pharmaceutical compounds and ongoing reporting and minimal operating expenses as previously described.

As of June 30, 2011, the Company had cash of $878,538 and prepaid expenses of $31,854. The Company had current liabilities of $325,055. This translates to total working capital of $585,337, which means that our cash reserves are not adequate to fund operations after December 31, 2011. We do not have any source of revenues as of June 30, 2011 and expect to rely on additional financing. The Company plans to seek private capital through the sale of additional restricted stock or borrowing either from principal shareholders or private parties; however we currently do not have plans to enter into such a transaction and there is no assurance that the Company will complete such a transaction.

In view of the lack of financing plans, the Company may be obliged to discontinue operations, which will adversely affect the value of its common stock. See "Risk Factors" in the Form 10-K.

Significant Subsequent Events

On July 7, 2011, the Company entered into a consulting agreement for clinical trials and other services to be provided to the Company over a 12 month period. As compensation, the Company has agreed to issue warrants to purchase 100,000 shares of the Company's common stock. The warrants will have an exercise price of $0.54 per share, which are exercisable for five years. In addition, the Company has agreed to issue 120,000 warrants to purchase common stock, vesting in equal tranches of 30,000 warrants per quarter. Such warrants will have an exercise price equal to the Company's market price at the time of each vesting tranche, and be exercisable for a period of five years.

On July 13, 2011, the Company announced the results of animal studies conducted using the Squalamine topical formulation.

Results of Operations

Three Months Ended June 30, 2011

Three months ended June 30, 2011 (“2011”) compared to the three months ended June 30, 2010 (“2010”). Results of operations for the three months ended June 30, 2011 reflect the following changes from the prior period.

	2011	2010	Change
Revenue	$ —	$ —	$ —
Cost of sales	—	—	—
General and administrative	(228,387)	(340,096)	(111,709)
Research and development	(73,144)	(14,497)	58,647
Interest expense	(84)	(2,495)	(2,411)
Gain (Loss) on derivative liability	(2,835,983)	140,969	2,976,952
Other income and expenses	50	39,514	39,464
Loss from operations	(3,137,548)	(176,605)	2,960,943
Discontinued operations	—	—	—
Net Loss	$ (3,137,548)	$ (176,605)	$ 2,960,943

The Company had no net revenues from continuing operations in the three months ended June 30, 2011. The Company's products are in the development stage.

The Company also had no cost of revenue from continuing operations in the three months ended June 30, 2011.

General and administrative expenses from continuing operations decreased from $340,096 in the three months ended June 30, 2010 to $228,387 in 2011. The decrease in general and administrative expenses during the three months ended June 30, 2011 is primarily due to a decrease in employee stock option expenses associated with stock options issued as incentive compensation in 2010. Partially offsetting the decrease in stock option expense, general payroll expenses related to the employment of our management team commencing in April 2010 have resulted in increases over the 2010 period. The Company expects general and administrative expenses to continue to increase in future periods as development of its products continues.

The Company incurred $73,144 in research and development expenses in the three months ended June 30, 2011 compared to $14,497 in 2010. The increase of $58,647 is a result of the commencement of animal studies and lab tests in 2011 as well as maintenance and development of the products that it acquired in 2009. The Company expects research and development expenses to continue to rise as development of its products continue.

The Company issued certain warrants to investors at various times that qualify for derivative accounting which requires that the value of these warrants be recorded as a liability instead of within equity. These warrants are then marked to their fair value at the end of each reporting period with changes being recorded in earnings. As the Company's stock price has increased during 2011, the value of these warrants has increased, resulting in an increase in the liability and a non-cash loss on derivative liability of $2,835,983 for 2011 compared to a gain of $140,969 in 2010.

For the three months ended June 30, 2011, the Company recognized net loss of $3,137,548 compared to a loss of $176,605 for the same period in 2010. Until the Company is able to generate revenues, management expects to continue to incur net losses. Excluding the non-cash gain or loss on derivative liability as well as the non-cash expense associated with the issuance of stock and warrants to employees and consultants, the Company's net loss for 2011 would have been $265,308 and $96,019 for 2010.

Nine Months Ended June 30, 2011

Nine months ended June 30, 2011 ("2011") compared to the nine months ended June 30, 2010 ("2010"). Results of operations for the nine months ended June 30, 2011 reflect the following changes from the prior period.

	2011	2010	Change
Revenue	$ —	$ —	$ —
Cost of sales	—	—	—
General and administrative	(517,362)	(613,544)	(96,182)
Research and development	(350,407)	(73,399)	277,008
Interest expense	(2,433)	(19,288)	(16,855)
Gain (Loss) on derivative liability	(2,945,196)	140,969	3,086,165
Other income and expenses	72,162	68,101	(4,061)
Loss from operations	(3,743,236)	(497,161)	3,246,075
Discontinued operations	—	—	—
Net Loss	$ (3,743,236)	$ (497,161)	$ 3,246,075

The Company had no net revenues from continuing operations in the nine months ended June 30, 2011. The Company's products are in the development stage.

The Company also had no cost of revenue from continuing operations in the nine months ended June 30, 2011.

General and administrative expenses from continuing operations decreased from $613,544 in the nine months ended June 30, 2010 to $517,362 in 2011. The decrease in general and administrative expenses during the three months ended June 30, 2011 is primarily due to a decrease in employee stock option expenses associated with stock options issued as incentive compensation in 2010. Partially offsetting the decrease in stock option expense, general payroll expenses related to the employment of our management team commencing in April 2010 and increased legal and accounting fees have resulted in increases over the 2010 period. The Company expects general and administrative expenses to continue to increase in future periods as development of its products continues.

The Company incurred $350,407 in research and development expenses in the nine months ended June 30, 2011 compared to $73,399 in 2010. The increase of $277,008 is a result of the commencement of animal studies and lab tests in 2011 as well as maintenance and development of the products that it acquired in 2009. The Company expects research and development expenses to continue to rise as development of its products continue.

The Company sold certain non-core assets for $87,500. The assets sold were acquired as part of a purchase of a larger portfolio of patents. The assets were not part of the targeted biotechnology sector strategy and management did not expect to be able to use or sell these assets during their useful lives and thus assigned an initial value of $0 to these assets. As part of the transaction, the Company incurred a broker's fee of $17,000. Accordingly, the Company recognized a gain on the sale of assets of $70,500, which was included in Other Income and Expenses.

The Company issued certain warrants to investors at various times that qualify for derivative accounting which requires that the value of these warrants be recorded as a liability instead of within equity. These warrants are then marked to their fair value at the end of each reporting period with changes being recorded in earnings. As the Company's stock price has increased during 2011, the value of these warrants has increased, resulting in an increase in the liability and a non-cash loss on derivative liability of $2,945,196 for 2011 compared to a gain of $140,969 in 2010.

For the nine months ended June 30, 2011, the Company recognized net loss of $3,743,236 compared to a loss of $497,161 for the same period in 2010. Until the Company is able to generate revenues, management expects to continue to incur net losses. Excluding the non-cash gain or loss on derivative liability as well as the non-cash expense associated with the issuance of stock and warrants to employees and consultants, the Company's net loss for 2011 would have been $727,765 and $342,002 for 2010.

Item 3. Quantitative and Qualitative Risk

Market risk represents the risk of loss arising from adverse changes in interest rates and foreign exchange rates. The Company does not have any material exposure to interest rate or exchange rate risk.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended ("Exchange Act")) that are designed to assure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosures.

As required by Exchange Act Rule 13a-15(b), as of the end of the period covered by this Quarterly Report, under the supervision and with the participation of our chief executive officer and chief financial officer, we evaluated the effectiveness of our disclosure controls and procedures. Based on this evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective as of that date.

Management’s Report on Internal Control over Financial Reporting

Management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) under the Exchange Act. Internal control over financial reporting is a process designed by, or under the supervision of, the chief executive officer and chief financial officer, and effected by the board of directors and management to provide reasonable assurance regarding the

reliability of financial reporting and the preparation of financial statements for external purposes in accordance with US Generally Accepted Accounting Principles ("GAAP") including those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of assets, (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with US GAAP and that receipts and expenditures are being made only in accordance with authorizations of management and the directors, and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect all errors and all fraud that could occur. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system's objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.

The Company knows of no fraudulent activities or any material accounting irregularities. The Company does not have an independent audit committee. The Company believes that an independent committee is not required for OTC Bulletin Board listings, but may further review the advisability and feasibility of establishing such a committee in the future.

The Company is aware of the general standards and requirements of the Sarbanes-Oxley Act of 2002 and has implemented procedures and rules to comply, so far as applicable, such as a prohibition on company loans to management and affiliates. The Company does not have any audit committee as it does not believe the act requires a separate committee for companies that are reporting companies, but not registered under the Securities and Exchange Act of 1934 (e.g., companies registered under Section 15(d)) and whose shares trade only on the OTC Bulletin Board.

This Quarterly Report does not include an attestation report of the Company's current independent registered public accounting firm regarding internal control over financial reporting. Management's report was not subject to attestation by the Company's current independent registered public accounting firm pursuant to rules of the SEC that permit the Company to provide only management's report in this Quarterly Report because the Company is a smaller reporting company under the SEC's rules.

Changes in Internal Control over Financial Reporting.

There were no changes in our internal control over financial reporting (as such term is defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) during our third fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II OTHER INFORMATION

Item 1. Legal Proceedings

Our management is not aware of any significant litigation, pending or threatened, that would have a significant adverse effect on our financial position or results of operations.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

On November 5, 2010 the Company issued 50,000 shares of common stock to a consultant for services. The shares were valued at $0.20 per share based on the market price of the shares on the date of issuance. The Company recorded the corresponding $10,000 expense to general and administrative expense.

On December 30, 2010 the Company sold 4,200,000 shares of common stock to a group of institutional and accredited investors for gross proceeds of $1,050,000. In connection with the financing, the investors received 2,520,000 five year warrants to purchase common stock at an exercise price of $0.55 per share. The exercise price of these warrants contains certain reset provisions which require the fair value of the warrants to be reported as a stock warrant derivative liability. On the date of issuance, the Company calculated the fair value of these warrants

to be $528,847. The total cash proceeds of $1,050,000 were first applied as an increase to stock warrant derivative liability with the remaining $521,153 being allocated to the common shares and being recorded in additional paid-in capital.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Removed and Reserved .

Item 5. Other Information

None.

Item 6. Exhibits

Exhibit	Number
10.21	Form of consulting warrants
31.1	Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of Chief Executive Officer Pursuant to 18 U.S.C Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2	Certification of Chief Financial Officer Pursuant to 18 U.S.C Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: August 15, 2011

OHR PHARMACEUTICAL, INC.
(Registrant)

By: /s/ Irach Taraporewala
Irach Taraporewala
Chief Executive Officer

By: /s/ Sam Backenroth
Sam Backenroth
Chief Financial Officer